Search by Drug Name or NDC

NDC 50474-0970-75 Briviact 50 mg/5mL Details

Briviact 50 mg/5mL

Briviact is a INTRAVENOUS INJECTION, SUSPENSION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by UCB, Inc.. The primary component is BRIVARACETAM.

MedlinePlus Drug Summary

Brivaracetam injection is used alone and in combination with other medications to control partial onset seizures (seizures that involve only one part of the brain) in adults, children, and infants 1 month of age or older who cannot take oral medication. Brivaracetam is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.

Related Packages: 50474-0970-75
Last Updated: 11/30/2022
MedLinePlus Full Drug Details: Brivaracetam Injection

Product Information

NDC	50474-0970
Product ID	50474-970_c6efa4e8-aa1f-4436-b0a7-2ccffb971275
Associated GPIs	72600015002050
GCN Sequence Number	075591
GCN Sequence Number Description	brivaracetam VIAL 50 MG/5 ML INTRAVEN
HIC3	H4B
HIC3 Description	ANTICONVULSANTS
GCN	40709
HICL Sequence Number	043088
HICL Sequence Number Description	BRIVARACETAM
Brand/Generic	Brand
Proprietary Name	Briviact
Proprietary Name Suffix	n/a
Non-Proprietary Name	brivaracetam
Product Type	HUMAN PRESCRIPTION DRUG
Dosage Form	INJECTION, SUSPENSION
Route	INTRAVENOUS
Active Ingredient Strength	50
Active Ingredient Units	mg/5mL
Substance Name	BRIVARACETAM
Labeler Name	UCB, Inc.
Pharmaceutical Class	Epoxide Hydrolase Inhibitors [MoA]
DEA Schedule	CV
Marketing Category	NDA
Application Number	NDA205837
Listing Certified Through	2024-12-31

Package

NDC 50474-0970-75 (50474097075)

Pricing Information	N/A
NDC Package Code	50474-970-75
Billing NDC	50474097075
Package	10 VIAL, GLASS in 1 CARTON (50474-970-75) / 5 mL in 1 VIAL, GLASS (50474-970-63)
Marketing Start Date	2016-05-12
NDC Exclude Flag	N